Sanofi and miRecule Partner to Develop Novel Antibody-RNA Conjugate for Muscular Dystrophy Therapy

By Swati Sharan

Pharma Deals Review: Vol 2022 Issue 11 (Table of Contents)

Published: 1 Nov-2022

DOI: 10.3833/pdr.v2022.i11.2743     ISSN: 1756-7874

Section: Research & Development



In a bid to broaden its rare disease franchise, Sanofi has entered into an exclusive license and collaboration agreement with miRecule to develop and commercialise an antibody-RNA conjugate, by combining the latter’s anti-DUX4 RNA therapy with Sanofi’s targeted NANOBODY technology, to treat patients suffering with facioscapulohumeral muscular dystrophy (FSHD)...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details